Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Saizeng Medical Licenses TSHR Antibody to Yarrow for $1.4B in Graves’ Disease Deal

Fineline Cube Dec 16, 2025
Company Deals

uBriGene Partners with Circurna on circRNA Manufacturing for Global Trials

Fineline Cube Dec 16, 2025
Company Deals

Dren Bio, Sanofi Forge $1.8B B‑Cell Therapy Deal with US Co‑Promote Option

Fineline Cube Dec 16, 2025
Company Deals

Adaptive Licenses TCR Data to Pfizer in $890M Deal for Rheumatoid Arthritis

Fineline Cube Dec 16, 2025
Company Deals

Sobi Acquires Arthrosi for $1.5 Billion to Add Gout Drug to Portfolio

Fineline Cube Dec 15, 2025
Policy / Regulatory

FDA Removes Key RWE Limitation, Allowing Drug and Device Submissions Without Individual Patient Data

Fineline Cube Dec 16, 2025
Company Drug

Orelabrutinib First BTK Inhibitor to Hit Phase 3 in Lupus as InnoCare NMPA Filing Cleared

Fineline Cube Dec 16, 2025
Company Drug

ENHERTU Wins FDA Approval as First-Line HER2 Breast Cancer Therapy

Fineline Cube Dec 16, 2025
Drug Policy / Regulatory

CDE Releases 65th Batch of Chemical Generic Reference Preparations

Fineline Cube Jan 3, 2023

The Center for Drug Evaluation (CDE) has released the 65th batch of chemical generic reference...

Company Drug Legal / IP

Viking Therapeutics Sues Ascletis Pharma Over Alleged Trade Secret Theft

Fineline Cube Jan 3, 2023

US – based Viking Therapeutics (NASDAQ: VKTX) is set to take China’s Ascletis Pharma Inc....

Company Deals

Shuwen Biotech Partners with Nottingham University Hospitals for MammaTyper

Fineline Cube Jan 3, 2023

China – based diagnostic specialist Shuwen Biotech Co., Ltd and its German wholly – owned...

Company Drug

Chinagene Tech’s ZVS101e Receives FDA IND Approval for Bietti’s Crystalline Dystrophy

Fineline Cube Jan 3, 2023

Beijing – based Chinagene Tech, a specialist in hereditary ophthalmopathy diagnosis and gene therapy, has...

Drug Policy / Regulatory

Jiangxi Leads 16-Province VBP Alliance with Winning Bids Announced

Fineline Cube Jan 3, 2023

The Jiangxi Province Healthcare Security Administration has released a notification regarding the winning bids of...

Company Medical Device

NMPA Approves 172 Medical Devices for Marketing in November 2022

Fineline Cube Dec 30, 2022

The National Medical Products Administration (NMPA) approved 172 medical devices for marketing in November 2022....

Company Drug

Merck’s Lagevrio Receives Emergency Conditional Approval from China’s NMPA

Fineline Cube Dec 30, 2022

US-based Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) has announced receiving emergency conditional approval...

Policy / Regulatory

NHSA and CNIPA Issue Opinions on Strengthening IP Protection in Drug Procurement

Fineline Cube Dec 30, 2022

The National Healthcare Security Administration (NHSA) and the China National Intellectual Property Administration (CNIPA) have...

Company Drug

Legend Biotech’s Carvykti Accepted for Review by China’s CDE

Fineline Cube Dec 30, 2022

The Center for Drug Evaluation (CDE) website indicates that a market approval filing from Legend...

Company Deals

F-star Therapeutics and Sino Biopharmaceutical Face Delays in Proposed Acquisition

Fineline Cube Dec 30, 2022

UK-based biotech F-star Therapeutics (NASDAQ: FSTX) released an SEC filing indicating that the proposed acquisition...

Company Drug

CSPC’s ALMB-0168 Receives NMPA Approval for Osteoarthritis Clinical Study

Fineline Cube Dec 30, 2022

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced receiving approval from the National Medical...

Company Drug

RemeGen’s RC108 Receives FDA Go-Ahead for Phase I Clinical Study

Fineline Cube Dec 30, 2022

China-based biopharma RemeGen Ltd (HKG: 9995) has announced receiving approval from the US FDA to...

Company Drug

Simcere Receives NMPA Clearance for SIM0348 Clinical Study

Fineline Cube Dec 30, 2022

China-based Simcere Pharmaceutical Group (HKG: 2096) has announced receiving clearance from the National Medical Products...

Company Deals

Skynor Medical Raises RMB 100 Million in Financing Round for Market Expansion

Fineline Cube Dec 30, 2022

Skynor Medical, a Shanghai-based manufacturer of nerve and peripheral blood vessel implantation and interventional devices,...

Company Deals

Sichuan Kelun Completes RMB 1.5 Billion Financing Round for Kelun-Biotech

Fineline Cube Dec 30, 2022

China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) has announced the completion of a financing...

Company Drug

Everest Medicines’ Nefecon Receives Priority Review Recommendation from CDE

Fineline Cube Dec 30, 2022

China-based Everest Medicines (HKG: 1952) has announced that the Center for Drug Evaluation (CDE) of...

Company Drug

BrightGene Receives NMPA Approval for BGM0504 Clinical Trial

Fineline Cube Dec 30, 2022

China-based BrightGene Bio-Medical Technology Co., Ltd (SHA: 688166) has announced that it has received clinical...

Drug

Anhui Anke Biotechnology Receives NMPA Approval for AK2017 Clinical Study

Fineline Cube Dec 30, 2022

China-based Anhui Anke Biotechnology (Group) Co., Ltd (SHE: 300009) has announced receiving approval from the...

Company Drug

AstraZeneca’s Nexium Approved by NMPA for Adolescent GERD Treatment

Fineline Cube Dec 30, 2022

UK-based pharmaceutical major AstraZeneca (NASDAQ: AZN) has announced receiving market approval from the National Medical...

Company Deals

Sino Biopharmaceutical Secures Rights to Shionogi’s COVID-19 Therapy Ensitrelvir

Fineline Cube Dec 30, 2022

China-based Sino Biopharmaceutical Ltd (HKG: 1177) has announced that its subsidiary Jiangsu Chia Tai Tianqing...

Posts pagination

1 … 512 513 514 … 598

Recent updates

  • Orelabrutinib First BTK Inhibitor to Hit Phase 3 in Lupus as InnoCare NMPA Filing Cleared
  • Saizeng Medical Licenses TSHR Antibody to Yarrow for $1.4B in Graves’ Disease Deal
  • Zhicheng’s TAVR Robotic System Enters NMPA Innovation Pathway
  • ENHERTU Wins FDA Approval as First-Line HER2 Breast Cancer Therapy
  • FDA Removes Key RWE Limitation, Allowing Drug and Device Submissions Without Individual Patient Data
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Orelabrutinib First BTK Inhibitor to Hit Phase 3 in Lupus as InnoCare NMPA Filing Cleared

Company Deals

Saizeng Medical Licenses TSHR Antibody to Yarrow for $1.4B in Graves’ Disease Deal

Company Medical Device

Zhicheng’s TAVR Robotic System Enters NMPA Innovation Pathway

Company Drug

ENHERTU Wins FDA Approval as First-Line HER2 Breast Cancer Therapy

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.